Search

Displaying results 1361 - 1370 of 7017 in total
  1. Drug

    Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen

    go.drugbank.com/drugs/DB16709
    Approved

    at the site from which the graft is taken. … [L35505] It was developed as an alternative to autografting - the process by which a patient's own skin is harvested and grafted onto the burn site - which has the disadvantage of creating a new wound

  2. Drug

    Tridihexethyl

    go.drugbank.com/drugs/DB00505
    ApprovedWithdrawn

    Tridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. … Tridihexethyl is an antimuscarinic, anticholinergic drug. Tridihexethyl is no longer available in the US market.

  3. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant … In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months

  4. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter. … [L48216] α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 interaction, leading to the mobilization of lymphocytes and thus contributing

  5. Drug

    Metipranolol

    go.drugbank.com/drugs/DB01214
    ApprovedWithdrawn

    A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.

  6. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    Sutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored odorless powder. … Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation.

  7. Drug

    Belinostat

    go.drugbank.com/drugs/DB05015
    ApprovedInvestigational

    It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. … It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget.

    Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  8. Drug

    Uric acid

    go.drugbank.com/drugs/DB08844
    Investigational

    At present (August 2013), there is no approved formulation or indication for uric acid. … As a therapeutic agent, it is known that uric acid is increased in response to oxidative stress, and as such, uric acid acts as an antioxidant.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a … Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  10. Drug

    Arnica montana flower

    go.drugbank.com/drugs/DB14343
    Approved

    Arnica montana flower is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: . - Gel